Gilead Hunting for Acquisitions - In an interview to the Financial Times, Nobert Bischofberger, Executive Vice President of Research and Development at Gilead Sciences (NASDAQ:GILD) said that the company is looking for acquisitions as it looks for another blockbuster drug. Gilead's Harvoni and Sovaldi have achieved blockbuster status. The HCV assets were acquired through an acquisition. Now the company is looking for similar assets as HCV treatment market matures. Gilead certainly has the resources to complete a major acquisition thanks to its cash position and the $10 billion it raised in a debt offering. Interestingly, Bischofberger said that the company would prefer to find an acquisition target that would complement its unit focusing on liver diseases. This is what I had predicted shortly after Gilead raised $10 billion through a debt offering. Acquiring an asset in the liver space would make strategic sense for Gilead.
Was gilead one of the big pharmas we were in discussions with?
Gilead aquiring in the liver space
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)